Chinese Cancer Drug Name Finder: Match Chinese Drug Names to International Generic Names
Confused by a Chinese prescription or treatment plan? This reference helps you identify a Chinese cancer drug by brand name, active ingredient, or generic name — with confirmation sources and confidence levels for each match.
This tool identifies names. It does not assess treatment suitability, verify package contents, or recommend any treatment change.
Quick Answer
Search by Chinese characters, pinyin, English generic name, or brand name. The result shows the proposed match, the name type, the confidence level, the source, and — critically — what the name alone does not tell you. If no reliable match is found, the tool says so rather than guessing.
"A name identifies a substance. A product identifies a medicine. A prescription identifies a treatment plan. Only your care team can connect all three."
Who This Tool Is Not For
This tool is not for patients seeking a treatment recommendation, a clinical eligibility assessment, or a guarantee that a specific Chinese product is genuine, approved, or available. It is for patients, families, and healthcare professionals who want to understand what a medicine name in a Chinese document likely refers to — and what still needs verification.
Search the Drug Reference
Use any drug name available in your document. Chinese characters are usually the most useful starting point when the original document is in Chinese.
Chinese generic name; immune checkpoint inhibitor; anti-PD-1 monoclonal antibody.
The Chinese generic name should be distinguished from any specific commercial product or formulation (e.g., Keytruda). A name match confirms the active substance, not the product.
The exact product, manufacturer, formulation, regulatory status, and the treatment indication described in the relevant official documentation.
"Does the document specify the manufacturer, formulation, and approval status of this product, and does it match the pembrolizumab formulation we would use?"
Chinese generic name; anti-PD-1 immune checkpoint inhibitor.
Distinguish the generic name from the brand name Opdivo. Confirm whether the document references a specific product or a generic equivalent.
Product identity, formulation, regulatory status in China, and the approved indication in the relevant documentation.
"Is the product in my document Opdivo or another manufacturer, and does the formulation match?"
Chinese generic name; anti-PD-1 immune checkpoint inhibitor; developed in China (Innovent).
The generic name should be separated from brand (Tyvyt) and manufacturer details.
Product identity, regulatory documentation in China and abroad, and the indication specified in the treatment plan.
"Is this the Tyvyt product, and what indications has it been approved for in the relevant jurisdiction?"
Chinese generic name; anti-PD-1 immune checkpoint inhibitor (BeiGene).
Distinguish from brand (Tevimbra) and from manufacturer-specific formulations.
Product identity, approval status in China and other jurisdictions, and the documented indication.
"Is this Tevimbra, and which indications is it approved for in the country of treatment?"
Chinese generic name; anti-PD-1 immune checkpoint inhibitor (Jiangsu Hengrui).
Distinguish from brand (AiRuiKa / SHR-1210 research code) and from other PD-1 inhibitors.
Whether the document refers to an approved product or a trial compound; approval status and indication.
"Is this an approved product in the country of treatment, or an investigational compound in a trial?"
Chinese generic name; anti-PD-1 immune checkpoint inhibitor (Junshi Biosciences).
The Chinese name is recognized, but the product may also appear under the brand name Tuoyi or under the research code JS001. Confirm which is used in the document.
Whether the document is referring to an approved product, a brand, or an investigational use.
"Is the product Tuoyi or another formulation, and is it approved for the intended indication?"
Chinese generic name; EGFR tyrosine kinase inhibitor (third generation).
Distinguish from brand (Tagrisso) and from earlier-generation EGFR TKIs (gefitinib, erlotinib). The name identifies the active substance, not the patient's molecular test result or eligibility for treatment.
Product identity and formulation, relevant product documentation, and the clinical context in which the medicine is proposed (including EGFR mutation status).
"Does my EGFR test result support osimertinib, and does the document confirm the Tagrisso formulation?"
Chinese generic name; ALK tyrosine kinase inhibitor.
Distinguish from other ALK inhibitors (crizotinib, ceritinib, lorlatinib). Confirm the specific ALK inhibitor in the document.
Product identity, approval status, and whether the document's dosing matches the alectinib regimen.
"Is this alectinib (Alecensa) or another ALK inhibitor, and does my ALK test result support it?"
Chinese generic name; first-generation EGFR tyrosine kinase inhibitor.
Distinguish from brand (Iressa) and from third-generation EGFR TKIs. Its role in treatment depends on the specific EGFR mutation.
Whether the current standard of care for the patient's mutation favors a first- or third-generation EGFR TKI.
"Given my EGFR mutation, is first-generation gefitinib the appropriate choice, or would a third-generation option be considered?"
Chinese generic name; BCR-ABL / KIT / PDGFR tyrosine kinase inhibitor.
Distinguish from brand (Gleevec / Glivec) and from generics manufactured in China. Many Chinese generics exist; confirm the manufacturer.
Which manufacturer produced the product, its regulatory status in China, and whether the intended indication matches the approved one.
"Which manufacturer produced this imatinib, and has it been approved for my indication?"
Chinese generic name; multi-target tyrosine kinase inhibitor (developed in China; Chia Tai Tianqing).
Approved in China under the brand Focus V. Its international availability is limited, so the Chinese name may not have an established international brand equivalent.
Whether the document refers to the Chinese-approved product, an investigational use, or a trial. Confirm the approval status in your jurisdiction.
"Is anlotinib approved in my country, and is it available outside China under another brand?"
Chinese generic name; HER2 tyrosine kinase inhibitor (developed in China; Hengrui).
Approved in China for HER2-positive breast cancer. Its role outside China is limited; confirm whether your jurisdiction recognizes the product.
Approval status outside China, and whether an alternative HER2-targeted therapy is available and appropriate in your jurisdiction.
"Is pyrotinib available and approved in my country, and if not, what HER2-targeted alternatives exist?"
Chinese generic name; multi-target tyrosine kinase inhibitor.
The name is well recognized, but its appearance in a document may also refer to a clinical trial, an off-label use, or a named-patient program. The name alone does not distinguish between these contexts.
The specific context (approved, off-label, or trial) and whether the product is the Stivarga brand or a generic equivalent.
"In what context is regorafenib being proposed in my document — approved use, off-label, or trial?"
Chinese generic name; taxane chemotherapy.
Paclitaxel appears in multiple formulations — conventional, albumin-bound (nab-paclitaxel), and liposomal. The Chinese generic name alone does not distinguish the formulation.
The formulation (conventional vs. nab-paclitaxel vs. liposomal) and the dosing schedule, both of which affect administration and side-effect profile.
"Which paclitaxel formulation is intended, and what is the administration schedule?"
Chinese generic name; platinum-based chemotherapy.
Distinguish from carboplatin (卡铂) and oxaliplatin (奥沙利铂). The three platinum agents have different toxicity profiles and indications.
Which platinum agent is intended, and whether the renal, neurologic, and hydration considerations match your clinical status.
"Is cisplatin the intended platinum agent, and have my kidney function and hearing been assessed for it?"
Chinese generic name; taxane chemotherapy.
Distinguish from paclitaxel (紫杉醇). Both are taxanes but have different dosing and toxicity profiles.
The intended taxane (docetaxel vs. paclitaxel) and whether the hypersensitivity prophylaxis protocol is documented.
"Is docetaxel the intended taxane, and what premedication protocol is planned to reduce hypersensitivity?"
Chinese generic name; HER2-targeted antibody–drug conjugate (ADC).
Distinguish from trastuzumab (曲妥珠单抗, without the cytotoxic payload) and from other HER2 ADCs (e.g., trastuzumab deruxtecan / DS-8201).
Which HER2-targeted agent is intended, and whether the treatment setting (adjuvant vs. metastatic) matches the approved indication.
"Is this T-DM1 (Kadcyla) or another HER2 ADC, and does it match the treatment setting?"
Chinese generic name; HER2-targeted ADC (developed in China; RemeGen).
Also known by the research code RC48. Approved in China for HER2-expressing cancers. Its international availability is limited.
Whether the document refers to the Chinese-approved product (Aidixi) or an investigational use; and the approval status in your jurisdiction.
"Is disitamab vedotin approved in my country, and is it available outside China?"
Chinese generic name; TROP2-targeted ADC.
The Chinese name is relatively new; some documents may use the brand name Trodelvy or the research code IMMU-132.
Whether the document refers to an approved product, a trial, or an investigational use. Confirm the manufacturer and the approval status in China.
"Is this Trodelvy or another sacituzumab govitecan product, and is it approved in my jurisdiction?"
Chinese generic name; selective estrogen receptor modulator (SERM).
Distinguish from aromatase inhibitors (anastrozole, letrozole, exemestane) and from fulvestrant. These act by different mechanisms.
Whether the intended endocrine therapy is tamoxifen or an aromatase inhibitor, which depends on menopausal status and other clinical factors.
"Given my menopausal status and ER/PR result, is tamoxifen the intended endocrine therapy?"
Chinese generic name; third-generation aromatase inhibitor.
Distinguish from anastrozole (阿那曲唑) and exemestane (依西美坦). All three are aromatase inhibitors but have different administration and side-effect profiles.
Which aromatase inhibitor is intended, and whether the patient's menopausal status supports its use.
"Is letrozole the intended aromatase inhibitor, and does my menopausal status support its use?"
Chinese generic name; corticosteroid used in supportive care (anti-emetic, anti-inflammatory, premedication).
Dexamethasone appears in many oncology regimens as supportive care, not as an anticancer therapy. Its role depends on the regimen context.
The dose, route, duration, and purpose of dexamethasone in the regimen (premedication, anti-emetic, or anti-inflammatory).
"What is the purpose of dexamethasone in this regimen, and what dose and duration are intended?"
Chinese generic name; 5-HT3 receptor antagonist used as anti-emetic.
Ondansetron is supportive care, not an anticancer therapy. It is often prescribed alongside chemotherapy to reduce nausea and vomiting.
The dose, route, and schedule, especially if the patient has cardiac risk factors (QT prolongation).
"Is ondansetron appropriate given my cardiac history, and what schedule is intended?"
Research code, not a registered generic name. Associated with camrelizumab (卡瑞利珠单抗).
A research code may refer to an investigational compound in a trial, not necessarily to an approved medicine. The name alone does not confirm regulatory status.
Whether the document refers to an approved camrelizumab product, a trial, or an investigational use. Confirm the trial identifier and regulatory status.
"Is SHR-1210 in my document an approved product or a trial compound, and what is the trial identifier if applicable?"
Illustrative research code used to demonstrate how an unverified match appears in the Finder.
This is not a real drug code. It illustrates the "unverified" state: the Finder cannot find a reliable match and explicitly says so.
If a research code is unverified, ask the hospital or trial team for the full product name, the trial identifier, and the regulatory status.
"Can you provide the full product name and trial identifier associated with this code?"
Understanding Match Confidence
A confidence label communicates the strength of the identification evidence — not the clinical suitability of the medicine.
Confirmed name match
The Chinese term is supported by a reliable reference that links it to the proposed generic or active-ingredient name. This confirms the terminology match only — not the physical product, approval, or eligibility.
Probable match
The available name and supporting information point to a likely match, but one or more identifying details remain unverified. The result states what information is missing.
Ambiguous match
Two or more products or substances could plausibly match the input. The system presents the ambiguity rather than choosing one without sufficient evidence.
Unverified / no reliable match
The available sources do not support a dependable identification. The user should check the original Chinese characters, provide additional product details, or seek confirmation from the prescribing hospital or pharmacist.
What If the Drug Name Cannot Be Identified?
Some names are difficult to match because they are abbreviated, handwritten, mistranslated, written phonetically, or associated with a product that has limited public documentation. If a result is uncertain, do not rely on a guessed match.
Information that may help establish the identity
- The exact Chinese characters as printed in the original document.
- The full product or brand name.
- The manufacturer or marketing authorization holder.
- The product approval or registration number, where applicable.
- The formulation and strength shown on the product label.
- A clear image of the relevant label or document section, with unnecessary personal information removed.
If the name still cannot be verified, ask the hospital or dispensing pharmacist to confirm the medicine's generic name and exact product identity. Do not use an uncertain match to decide which medicine to purchase, administer, stop, or substitute.
Frequently Asked Questions
Can I identify a Chinese cancer medicine using only its Chinese name?
Sometimes. A recognized Chinese generic name may be sufficient to identify an active substance. A brand name, abbreviation, research code, or incomplete term may require additional information.
Does a matching international name prove that the Chinese product is approved?
No. Name matching and regulatory verification are separate tasks. Approval status must be checked against the relevant official regulatory record, including the applicable product and indication where that information is available.
Does the Finder tell me whether the medicine is available in my country?
Not automatically. Availability, authorization, supply, and reimbursement differ between countries and can change over time. Any country-specific information requires separate verification.
Can I use the Finder to decide whether a drug is right for my cancer?
No. The Finder helps identify terminology and products. It does not assess individual treatment eligibility or compare the clinical benefits and risks of different options.
Can I identify a clinical-trial drug by its code?
A research code may help locate public trial or development records, but a code alone may not establish a unique international generic name. Some investigational products have no approved INN or may be described differently across documents.
What if two medicines have similar names?
Do not assume they are the same medicine. The Finder flags ambiguous matches and requests further identifying information rather than presenting an unsupported conclusion.
Can the Finder verify that a medicine in a package is genuine?
No. A text-based name match cannot authenticate a physical product. Authenticity requires appropriate supply-chain, product, and regulatory verification.
Is the Finder a substitute for a pharmacist or oncologist?
No. It is an information reference intended to help users understand medicine names and prepare better questions for the healthcare professionals responsible for their care.
Identify the Name. Prepare the Question.
If you received a Chinese prescription or treatment plan and want help understanding what to verify before your next appointment, you can request a free information review. We do not charge patient fees, and we do not provide medical advice or guarantee access to any treatment.
Continue Exploring
Chinese Pathology Report Decoder
Decode pathology terminology with pinyin and multilingual explanations.
30 Terms That Must Not Be Misinterpreted
High-risk translation errors in Chinese medical reports.
When NOT to Go to China
A decision framework for when travel should pause.
CancerCareE FAQ
How the platform works and our $0 patient fee model.
Sources & Verification Standards
- World Health Organization — International Nonproprietary Names (INN) programme. who.int
- National Cancer Institute — NCI Drug Dictionary. cancer.gov
- National Medical Products Administration (NMPA) — China. nmpa.gov.cn
- CancerCareE Editorial Policy — Source-cited content; no claim of medical review unless documented.
- Manufacturer product information — when needed to resolve brand, formulation, or approval questions.
Note on data currency: This prototype includes 25 illustrative drug records. The production version requires a fully verified, source-cited database with per-drug review records. Verify all entries against WHO INN, NCI Drug Dictionary, and NMPA records before any clinical, purchasing, or regulatory decision.